SNNAQ.US Sienna Biopharmaceuticals Inc
- Market cap
- USD 3.09K
- P/E
- -
- P/B
- 0.00x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2022.
Is SNNAQ.US undervalued?
Graham numberThe Graham number of Sienna Biopharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sienna Biopharmaceuticals Inc fundamental analysis
No fundamental analysis for Sienna Biopharmaceuticals Inc yet.
Sienna Biopharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sienna Biopharmaceuticals Inc
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a top…
Full company profileSienna Biopharmaceuticals Inc financial statements
Sienna Biopharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | - | - | - | - |
| Gross Profit | -32.0K | -67.0K | -120K | -157K | - | - | - | - |
| Operating Income | -11.1M | -20.7M | -48.6M | -76.5M | - | - | - | - |
| EBITDA | -11.1M | -20.6M | -48.5M | -76.3M | - | - | - | - |
| Net Income | -11.3M | -21.8M | -50.5M | -73.3M | - | - | - | - |
| EPS | -5.81 | -11 | -5.19 | -3.59 | - | - | - | - |
| Balance Sheet | ||||||||
| Total Assets | 5.75M | 62.4M | 137M | 107M | - | - | - | - |
| Total Liabilities | 1.70M | 40.3M | 45.6M | 80.7M | - | - | - | - |
| Shareholders' Equity | 4.05M | 22.1M | 85.9M | 159M | - | - | - | - |
| Cash & Short-term Investments | 4.96M | 9.09M | 74.5M | 48.5M | - | - | - | - |
| Total Debt | - | - | - | 30.1M | - | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -9.98M | -17.7M | -41.1M | -61.7M | - | - | - | - |
| Capital Expenditure | 88.0K | 238K | 274K | 39.0K | 0.00 | - | - | - |
| Free Cash Flow | -10.1M | -17.9M | -41.4M | -61.7M | - | - | - | - |
| Ratios | ||||||||
| ROE | -278.8% | -98.7% | -58.8% | -46.0% | - | - | - | - |
| ROA | -196.3% | -35.0% | -36.9% | -68.3% | - | - | - | - |
| Debt to Equity | - | - | - | 0.19x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sienna Biopharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
| 2015 | USD 45.4M | 23 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Sienna Biopharmaceuticals Inc
- Insiders 0.00%
- Institutions 4.33%
- Public & others 95.67%
- Shares outstanding 30.9M
- Free float 30.8M
Sienna Biopharmaceuticals Inc company profile
- Company name
- Sienna Biopharmaceuticals Inc
- Ticker
- SNNAQ.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Fiscal year end
- December
- Address
- 30699 Russell Ranch Road, Westlake Village, CA, United States, 91362
- Phone
- 818-629-2256
- Website
- siennabio.com
About Sienna Biopharmaceuticals Inc
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019.
Sienna Biopharmaceuticals Inc management
2- Mr. Theodore SchwartzHead of Global Strategic Marketing · born 1961
- Dr. David E. I. Pyott M.A., M.B.A., M.D.Strategic Advisor to the Board and CEO · born 1953